A chromatographic digital immunoassay for the rapid, qualitative detection of SARSCoV2 (COVID19) nucleocapsid protein antigens directly in anterior nasal swab specimens from individuals with signs and symptoms of the upper respiratory infection. Intended for use as an aid in diagnosing symptomatic individuals when they tested at least twice over 3 days with at least 48 hours between tests, or they tested negative once by the BD Veritor™ System for SARSCoV2 and followed up with a molecular test. CLIA waived.